CARISMA Therapeutics (CARISMA Therapeutics) Median PS Value : $0.00 (As of Jun. 05, 2024)

CARISMA Therapeutics Median PS Value Chart

CARISMA Therapeutics Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Median PS Value	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of CARISMA Therapeutics's Median PS Value

For the Biotechnology subindustry, CARISMA Therapeutics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CARISMA Therapeutics's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where CARISMA Therapeutics's Price-to-Median-PS-Value falls into.

CARISMA Therapeutics Median PS Value Calculation

CARISMA Therapeutics's Median PS Value for today is calculated as

10-Year Median PS Ratio is 0.
CARISMA Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.372.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics  (NAS:CARM) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

CARISMA Therapeutics's Price to Median PS Value for today is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CARISMA Therapeutics Median PS Value Related Terms

Thank you for viewing the detailed overview of CARISMA Therapeutics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.

CARISMA Therapeutics (CARISMA Therapeutics) Business Description